BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
But, you know, why is it that the monotherapy did so well in terms of the CR rate? I think it's the endpoint that is being measured. You know, if you're measuring a local endpoint. and you're giving a local therapy, the local therapy is going to shine. But why didn't it shine when it was in combination with the checkpoint?
0
💬
0
Comments
Log in to comment.
There are no comments yet.